Targeted Therapy

Targeted Therapy

If you have been NEWLY DIAGNOSED  START HERE 

Video Library

We are excited to share with you more videos from a recent series of discussions between Drs. Howard (Jack) West, MD, Associate Clinical Professor,...
Cancer Journey:
Cancer Type:
We are excited to share with you more videos from a recent series of discussions between Drs. Howard (Jack) West, MD, Associate Clinical Professor,...
Cancer Journey:
Cancer Type:
We are excited to share with you more videos from a recent series of discussions between Drs. Howard (Jack) West, MD, Associate Clinical Professor,...
Cancer Journey:
Cancer Type:
We are excited to share with you more videos from a recent series of discussions between Drs. Howard (Jack) West, MD, Associate Clinical Professor,...
Cancer Journey:
Cancer Type:
We are excited to share with you a recent series of discussions between Drs. Howard (Jack) West, MD, Associate Clinical Professor, Medical Oncology,...
Cancer Journey:
Cancer Type:

Articles

With positive trials of two immune checkpoint inhibitors, Opdivo (nivolumab) and Keytruda (pembrolizumab), in second line NSCLC and compared with...
Cancer Journey:
Cancer Type:
Yesterday, news that the Checkmate 026 trial that compared the PD1 checkpoint inhibitor Opdivo (nivolumab) to standard chemotherapy as first line...
Cancer Journey:
Cancer Type:
Probably the most immediate potentially practice-changing presentation from ASCO was the Japanese J-ALEX study in the subset of about 4-5% of...
Cancer Journey:
Cancer Type:
For patients with an activating EGFR mutation and who develop “acquired resistance”, the pattern of progression that occurs after a sometimes long...
Cancer Journey:
Cancer Type:
Disease Learning:
Dr. Edward S. Kim from the Levine Cancer Institute in Charlotte, NC discusses the feasibility of molecular marker testing and targeted therapy in the adjuvant or post-operative setting.
Cancer Journey:
Cancer Type:

Community Forum

No Result Found